Predictive factors for outcomes after reduced intensity conditioning hematopoietic stem cell transplantation for hematological malignancies: a 10-year retrospective analysis from the Société Française de Greffe de Moelle et de Thérapie Cellulaire
This retrospective study analyzed the impact of demographic and transplantation variables on outcomes of 1108 patients who have undergone allogeneic hematopoietic stem cell transplantation after reduced intensity conditioning (RIC HSCT) for hematological malignancies and were reported to the Société...
Gespeichert in:
| Veröffentlicht in: | Experimental hematology 2008-05, Vol.36 (5), p.535-544 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 544 |
|---|---|
| container_issue | 5 |
| container_start_page | 535 |
| container_title | Experimental hematology |
| container_volume | 36 |
| creator | Michallet, Mauricette Le, Quoc-Hung Mohty, Mohamad Prébet, Thomas Nicolini, Franck Boiron, Jean Michel Esperou, Hélène Attal, Michel Milpied, Noel Lioure, Bruno Bordigoni, Pierre Yakoub-Agha, Ibrahim Bourhis, Jean-Henri Rio, Bernard Deconinck, Eric Renaud, Marc Chir, Zina Blaise, Didier |
| description | This retrospective study analyzed the impact of demographic and transplantation variables on outcomes of 1108 patients who have undergone allogeneic hematopoietic stem cell transplantation after reduced intensity conditioning (RIC HSCT) for hematological malignancies and were reported to the Société Française de Greffe de Moelle et de Thérapie Cellulaire registry between November 1994 and December 2004. Only 442 patients (40%) were in complete remission (CR) at time of transplantation. Peripheral blood stem cells were used in the majority of patients (n = 878; 79%), 255 patients received fludarabine and low-dose total body irradiation, while 465 patients (42%) fludarabine and busulfan with rabbit anti-thymocyte globulins (ATG). The impact of demographic and transplant variables was studied on overall (OS) and event-free survival (EFS) in univariate and multivariate analysis. With a median follow-up of 21 months, 3-year probability of OS and EFS was 42% and 30%, respectively, and treatment-related mortality was 15% at 2 years. The multivariate analysis showed a significant negative impact on OS and EFS of the absence of CR status before transplantation; conditioning regimen, including >10 mg/kg ATG; and minor ABO incompatibility. In conclusion, this study highlights the major impact on RIC HSCT outcome of disease status before transplantation, ATG dose and ABO incompatibility. |
| doi_str_mv | 10.1016/j.exphem.2008.01.017 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_inserm_00484237v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0301472X08000532</els_id><sourcerecordid>69147893</sourcerecordid><originalsourceid>FETCH-LOGICAL-c498t-d5adf461d69d146da50db3a5d739c9683a9a01683a5d27dc23e329ecb898b8303</originalsourceid><addsrcrecordid>eNqFUtGKEzEUHURx19U_EMmTT7Ymk2kn44OwFHdXqCjsCr6F2-ROmzqTzCaZYr9I-h39K5_M7BQFX4RAksvJuTfnnCx7yeiUUTZ_u53ij26D7TSnVEwpS6t8lJ0zUfJJzqvqcXZOOWWTosy_nWXPQthSSmezij7NzpjgxVxwcZ79-uJRGxXNDkkNKjofSO08cX1UrsVAoI7oSQL1CjUxNqINJu6JclabaJw1dk3SGBBd5wxGo0iI2BKFTUOiBxu6BmyEAfrAPGIbtzYKGtJCY9YWrDIY3hEgjE72CEPD6F3ocJwMLDT7YNJo3rUkbpDcOmWOh3g8kKvU4_gTTECikVx7rOuH0yeXJkCCcbjcbY4HD51BskjVvgHj8Xn2pIYm4IvTfpF9vfpwt7iZLD9ff1xcLieqqESc6BnoupgzPa80K-YaZlSvOMx0yStVJRWhguSHGEp5qVXOkecVqpWoxEpwyi-yNyPvBhrZedOC30sHRt5cLqWxAX0rKS1EkfNyxxL89QjvvLvvMUTZmjCoCRZdH-S8YkUpKp6AxQhUSamQ_v2HnFE5RERu5RgROUREUpZWmZ69OvH3qxb130enTCTA-xGASZSdQS9Dcscm-5NoKkrtzP86_EugGmMHu7_jHsPW9T75GSSTIZdU3g4xHVJKxZBQnvPf1hDt3w</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>69147893</pqid></control><display><type>article</type><title>Predictive factors for outcomes after reduced intensity conditioning hematopoietic stem cell transplantation for hematological malignancies: a 10-year retrospective analysis from the Société Française de Greffe de Moelle et de Thérapie Cellulaire</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Michallet, Mauricette ; Le, Quoc-Hung ; Mohty, Mohamad ; Prébet, Thomas ; Nicolini, Franck ; Boiron, Jean Michel ; Esperou, Hélène ; Attal, Michel ; Milpied, Noel ; Lioure, Bruno ; Bordigoni, Pierre ; Yakoub-Agha, Ibrahim ; Bourhis, Jean-Henri ; Rio, Bernard ; Deconinck, Eric ; Renaud, Marc ; Chir, Zina ; Blaise, Didier</creator><creatorcontrib>Michallet, Mauricette ; Le, Quoc-Hung ; Mohty, Mohamad ; Prébet, Thomas ; Nicolini, Franck ; Boiron, Jean Michel ; Esperou, Hélène ; Attal, Michel ; Milpied, Noel ; Lioure, Bruno ; Bordigoni, Pierre ; Yakoub-Agha, Ibrahim ; Bourhis, Jean-Henri ; Rio, Bernard ; Deconinck, Eric ; Renaud, Marc ; Chir, Zina ; Blaise, Didier</creatorcontrib><description>This retrospective study analyzed the impact of demographic and transplantation variables on outcomes of 1108 patients who have undergone allogeneic hematopoietic stem cell transplantation after reduced intensity conditioning (RIC HSCT) for hematological malignancies and were reported to the Société Française de Greffe de Moelle et de Thérapie Cellulaire registry between November 1994 and December 2004. Only 442 patients (40%) were in complete remission (CR) at time of transplantation. Peripheral blood stem cells were used in the majority of patients (n = 878; 79%), 255 patients received fludarabine and low-dose total body irradiation, while 465 patients (42%) fludarabine and busulfan with rabbit anti-thymocyte globulins (ATG). The impact of demographic and transplant variables was studied on overall (OS) and event-free survival (EFS) in univariate and multivariate analysis. With a median follow-up of 21 months, 3-year probability of OS and EFS was 42% and 30%, respectively, and treatment-related mortality was 15% at 2 years. The multivariate analysis showed a significant negative impact on OS and EFS of the absence of CR status before transplantation; conditioning regimen, including >10 mg/kg ATG; and minor ABO incompatibility. In conclusion, this study highlights the major impact on RIC HSCT outcome of disease status before transplantation, ATG dose and ABO incompatibility.</description><identifier>ISSN: 0301-472X</identifier><identifier>EISSN: 1873-2399</identifier><identifier>DOI: 10.1016/j.exphem.2008.01.017</identifier><identifier>PMID: 18346838</identifier><language>eng</language><publisher>Netherlands: Elsevier Inc</publisher><subject>Adolescent ; Adult ; Advanced Basic Science ; Aged ; Antilymphocyte Serum ; Antilymphocyte Serum - administration & dosage ; Busulfan ; Busulfan - administration & dosage ; Child ; Child, Preschool ; Disease-Free Survival ; Female ; Follow-Up Studies ; France ; Graft vs Host Disease ; Graft vs Host Disease - diagnosis ; Graft vs Host Disease - etiology ; Graft vs Host Disease - therapy ; Hematologic Neoplasms ; Hematologic Neoplasms - diagnosis ; Hematologic Neoplasms - therapy ; Hematology, Oncology and Palliative Medicine ; Hematopoietic Stem Cell Transplantation ; Hematopoietic Stem Cell Transplantation - adverse effects ; Humans ; Immunology ; Infant ; Life Sciences ; Male ; Middle Aged ; Multivariate Analysis ; Predictive Value of Tests ; Registries ; Remission Induction ; Retrospective Studies ; Risk Factors ; Survival Analysis ; Time ; Transplantation Conditioning ; Transplantation Conditioning - methods ; Transplantation, Homologous ; Treatment Outcome ; Vidarabine ; Vidarabine - administration & dosage ; Vidarabine - analogs & derivatives</subject><ispartof>Experimental hematology, 2008-05, Vol.36 (5), p.535-544</ispartof><rights>ISEH - Society for Hematology and Stem Cells</rights><rights>2008 ISEH - Society for Hematology and Stem Cells</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c498t-d5adf461d69d146da50db3a5d739c9683a9a01683a5d27dc23e329ecb898b8303</citedby><cites>FETCH-LOGICAL-c498t-d5adf461d69d146da50db3a5d739c9683a9a01683a5d27dc23e329ecb898b8303</cites><orcidid>0000-0003-4524-8782 ; 0000-0001-8536-7781 ; 0000-0002-7264-808X ; 0000-0002-7338-1081 ; 0000-0002-6006-8088</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0301472X08000532$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,776,780,881,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18346838$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://inserm.hal.science/inserm-00484237$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Michallet, Mauricette</creatorcontrib><creatorcontrib>Le, Quoc-Hung</creatorcontrib><creatorcontrib>Mohty, Mohamad</creatorcontrib><creatorcontrib>Prébet, Thomas</creatorcontrib><creatorcontrib>Nicolini, Franck</creatorcontrib><creatorcontrib>Boiron, Jean Michel</creatorcontrib><creatorcontrib>Esperou, Hélène</creatorcontrib><creatorcontrib>Attal, Michel</creatorcontrib><creatorcontrib>Milpied, Noel</creatorcontrib><creatorcontrib>Lioure, Bruno</creatorcontrib><creatorcontrib>Bordigoni, Pierre</creatorcontrib><creatorcontrib>Yakoub-Agha, Ibrahim</creatorcontrib><creatorcontrib>Bourhis, Jean-Henri</creatorcontrib><creatorcontrib>Rio, Bernard</creatorcontrib><creatorcontrib>Deconinck, Eric</creatorcontrib><creatorcontrib>Renaud, Marc</creatorcontrib><creatorcontrib>Chir, Zina</creatorcontrib><creatorcontrib>Blaise, Didier</creatorcontrib><title>Predictive factors for outcomes after reduced intensity conditioning hematopoietic stem cell transplantation for hematological malignancies: a 10-year retrospective analysis from the Société Française de Greffe de Moelle et de Thérapie Cellulaire</title><title>Experimental hematology</title><addtitle>Exp Hematol</addtitle><description>This retrospective study analyzed the impact of demographic and transplantation variables on outcomes of 1108 patients who have undergone allogeneic hematopoietic stem cell transplantation after reduced intensity conditioning (RIC HSCT) for hematological malignancies and were reported to the Société Française de Greffe de Moelle et de Thérapie Cellulaire registry between November 1994 and December 2004. Only 442 patients (40%) were in complete remission (CR) at time of transplantation. Peripheral blood stem cells were used in the majority of patients (n = 878; 79%), 255 patients received fludarabine and low-dose total body irradiation, while 465 patients (42%) fludarabine and busulfan with rabbit anti-thymocyte globulins (ATG). The impact of demographic and transplant variables was studied on overall (OS) and event-free survival (EFS) in univariate and multivariate analysis. With a median follow-up of 21 months, 3-year probability of OS and EFS was 42% and 30%, respectively, and treatment-related mortality was 15% at 2 years. The multivariate analysis showed a significant negative impact on OS and EFS of the absence of CR status before transplantation; conditioning regimen, including >10 mg/kg ATG; and minor ABO incompatibility. In conclusion, this study highlights the major impact on RIC HSCT outcome of disease status before transplantation, ATG dose and ABO incompatibility.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Advanced Basic Science</subject><subject>Aged</subject><subject>Antilymphocyte Serum</subject><subject>Antilymphocyte Serum - administration & dosage</subject><subject>Busulfan</subject><subject>Busulfan - administration & dosage</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Disease-Free Survival</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>France</subject><subject>Graft vs Host Disease</subject><subject>Graft vs Host Disease - diagnosis</subject><subject>Graft vs Host Disease - etiology</subject><subject>Graft vs Host Disease - therapy</subject><subject>Hematologic Neoplasms</subject><subject>Hematologic Neoplasms - diagnosis</subject><subject>Hematologic Neoplasms - therapy</subject><subject>Hematology, Oncology and Palliative Medicine</subject><subject>Hematopoietic Stem Cell Transplantation</subject><subject>Hematopoietic Stem Cell Transplantation - adverse effects</subject><subject>Humans</subject><subject>Immunology</subject><subject>Infant</subject><subject>Life Sciences</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Multivariate Analysis</subject><subject>Predictive Value of Tests</subject><subject>Registries</subject><subject>Remission Induction</subject><subject>Retrospective Studies</subject><subject>Risk Factors</subject><subject>Survival Analysis</subject><subject>Time</subject><subject>Transplantation Conditioning</subject><subject>Transplantation Conditioning - methods</subject><subject>Transplantation, Homologous</subject><subject>Treatment Outcome</subject><subject>Vidarabine</subject><subject>Vidarabine - administration & dosage</subject><subject>Vidarabine - analogs & derivatives</subject><issn>0301-472X</issn><issn>1873-2399</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFUtGKEzEUHURx19U_EMmTT7Ymk2kn44OwFHdXqCjsCr6F2-ROmzqTzCaZYr9I-h39K5_M7BQFX4RAksvJuTfnnCx7yeiUUTZ_u53ij26D7TSnVEwpS6t8lJ0zUfJJzqvqcXZOOWWTosy_nWXPQthSSmezij7NzpjgxVxwcZ79-uJRGxXNDkkNKjofSO08cX1UrsVAoI7oSQL1CjUxNqINJu6JclabaJw1dk3SGBBd5wxGo0iI2BKFTUOiBxu6BmyEAfrAPGIbtzYKGtJCY9YWrDIY3hEgjE72CEPD6F3ocJwMLDT7YNJo3rUkbpDcOmWOh3g8kKvU4_gTTECikVx7rOuH0yeXJkCCcbjcbY4HD51BskjVvgHj8Xn2pIYm4IvTfpF9vfpwt7iZLD9ff1xcLieqqESc6BnoupgzPa80K-YaZlSvOMx0yStVJRWhguSHGEp5qVXOkecVqpWoxEpwyi-yNyPvBhrZedOC30sHRt5cLqWxAX0rKS1EkfNyxxL89QjvvLvvMUTZmjCoCRZdH-S8YkUpKp6AxQhUSamQ_v2HnFE5RERu5RgROUREUpZWmZ69OvH3qxb130enTCTA-xGASZSdQS9Dcscm-5NoKkrtzP86_EugGmMHu7_jHsPW9T75GSSTIZdU3g4xHVJKxZBQnvPf1hDt3w</recordid><startdate>20080501</startdate><enddate>20080501</enddate><creator>Michallet, Mauricette</creator><creator>Le, Quoc-Hung</creator><creator>Mohty, Mohamad</creator><creator>Prébet, Thomas</creator><creator>Nicolini, Franck</creator><creator>Boiron, Jean Michel</creator><creator>Esperou, Hélène</creator><creator>Attal, Michel</creator><creator>Milpied, Noel</creator><creator>Lioure, Bruno</creator><creator>Bordigoni, Pierre</creator><creator>Yakoub-Agha, Ibrahim</creator><creator>Bourhis, Jean-Henri</creator><creator>Rio, Bernard</creator><creator>Deconinck, Eric</creator><creator>Renaud, Marc</creator><creator>Chir, Zina</creator><creator>Blaise, Didier</creator><general>Elsevier Inc</general><general>Elsevier</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>1XC</scope><orcidid>https://orcid.org/0000-0003-4524-8782</orcidid><orcidid>https://orcid.org/0000-0001-8536-7781</orcidid><orcidid>https://orcid.org/0000-0002-7264-808X</orcidid><orcidid>https://orcid.org/0000-0002-7338-1081</orcidid><orcidid>https://orcid.org/0000-0002-6006-8088</orcidid></search><sort><creationdate>20080501</creationdate><title>Predictive factors for outcomes after reduced intensity conditioning hematopoietic stem cell transplantation for hematological malignancies: a 10-year retrospective analysis from the Société Française de Greffe de Moelle et de Thérapie Cellulaire</title><author>Michallet, Mauricette ; Le, Quoc-Hung ; Mohty, Mohamad ; Prébet, Thomas ; Nicolini, Franck ; Boiron, Jean Michel ; Esperou, Hélène ; Attal, Michel ; Milpied, Noel ; Lioure, Bruno ; Bordigoni, Pierre ; Yakoub-Agha, Ibrahim ; Bourhis, Jean-Henri ; Rio, Bernard ; Deconinck, Eric ; Renaud, Marc ; Chir, Zina ; Blaise, Didier</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c498t-d5adf461d69d146da50db3a5d739c9683a9a01683a5d27dc23e329ecb898b8303</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Advanced Basic Science</topic><topic>Aged</topic><topic>Antilymphocyte Serum</topic><topic>Antilymphocyte Serum - administration & dosage</topic><topic>Busulfan</topic><topic>Busulfan - administration & dosage</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Disease-Free Survival</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>France</topic><topic>Graft vs Host Disease</topic><topic>Graft vs Host Disease - diagnosis</topic><topic>Graft vs Host Disease - etiology</topic><topic>Graft vs Host Disease - therapy</topic><topic>Hematologic Neoplasms</topic><topic>Hematologic Neoplasms - diagnosis</topic><topic>Hematologic Neoplasms - therapy</topic><topic>Hematology, Oncology and Palliative Medicine</topic><topic>Hematopoietic Stem Cell Transplantation</topic><topic>Hematopoietic Stem Cell Transplantation - adverse effects</topic><topic>Humans</topic><topic>Immunology</topic><topic>Infant</topic><topic>Life Sciences</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Multivariate Analysis</topic><topic>Predictive Value of Tests</topic><topic>Registries</topic><topic>Remission Induction</topic><topic>Retrospective Studies</topic><topic>Risk Factors</topic><topic>Survival Analysis</topic><topic>Time</topic><topic>Transplantation Conditioning</topic><topic>Transplantation Conditioning - methods</topic><topic>Transplantation, Homologous</topic><topic>Treatment Outcome</topic><topic>Vidarabine</topic><topic>Vidarabine - administration & dosage</topic><topic>Vidarabine - analogs & derivatives</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Michallet, Mauricette</creatorcontrib><creatorcontrib>Le, Quoc-Hung</creatorcontrib><creatorcontrib>Mohty, Mohamad</creatorcontrib><creatorcontrib>Prébet, Thomas</creatorcontrib><creatorcontrib>Nicolini, Franck</creatorcontrib><creatorcontrib>Boiron, Jean Michel</creatorcontrib><creatorcontrib>Esperou, Hélène</creatorcontrib><creatorcontrib>Attal, Michel</creatorcontrib><creatorcontrib>Milpied, Noel</creatorcontrib><creatorcontrib>Lioure, Bruno</creatorcontrib><creatorcontrib>Bordigoni, Pierre</creatorcontrib><creatorcontrib>Yakoub-Agha, Ibrahim</creatorcontrib><creatorcontrib>Bourhis, Jean-Henri</creatorcontrib><creatorcontrib>Rio, Bernard</creatorcontrib><creatorcontrib>Deconinck, Eric</creatorcontrib><creatorcontrib>Renaud, Marc</creatorcontrib><creatorcontrib>Chir, Zina</creatorcontrib><creatorcontrib>Blaise, Didier</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><jtitle>Experimental hematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Michallet, Mauricette</au><au>Le, Quoc-Hung</au><au>Mohty, Mohamad</au><au>Prébet, Thomas</au><au>Nicolini, Franck</au><au>Boiron, Jean Michel</au><au>Esperou, Hélène</au><au>Attal, Michel</au><au>Milpied, Noel</au><au>Lioure, Bruno</au><au>Bordigoni, Pierre</au><au>Yakoub-Agha, Ibrahim</au><au>Bourhis, Jean-Henri</au><au>Rio, Bernard</au><au>Deconinck, Eric</au><au>Renaud, Marc</au><au>Chir, Zina</au><au>Blaise, Didier</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Predictive factors for outcomes after reduced intensity conditioning hematopoietic stem cell transplantation for hematological malignancies: a 10-year retrospective analysis from the Société Française de Greffe de Moelle et de Thérapie Cellulaire</atitle><jtitle>Experimental hematology</jtitle><addtitle>Exp Hematol</addtitle><date>2008-05-01</date><risdate>2008</risdate><volume>36</volume><issue>5</issue><spage>535</spage><epage>544</epage><pages>535-544</pages><issn>0301-472X</issn><eissn>1873-2399</eissn><abstract>This retrospective study analyzed the impact of demographic and transplantation variables on outcomes of 1108 patients who have undergone allogeneic hematopoietic stem cell transplantation after reduced intensity conditioning (RIC HSCT) for hematological malignancies and were reported to the Société Française de Greffe de Moelle et de Thérapie Cellulaire registry between November 1994 and December 2004. Only 442 patients (40%) were in complete remission (CR) at time of transplantation. Peripheral blood stem cells were used in the majority of patients (n = 878; 79%), 255 patients received fludarabine and low-dose total body irradiation, while 465 patients (42%) fludarabine and busulfan with rabbit anti-thymocyte globulins (ATG). The impact of demographic and transplant variables was studied on overall (OS) and event-free survival (EFS) in univariate and multivariate analysis. With a median follow-up of 21 months, 3-year probability of OS and EFS was 42% and 30%, respectively, and treatment-related mortality was 15% at 2 years. The multivariate analysis showed a significant negative impact on OS and EFS of the absence of CR status before transplantation; conditioning regimen, including >10 mg/kg ATG; and minor ABO incompatibility. In conclusion, this study highlights the major impact on RIC HSCT outcome of disease status before transplantation, ATG dose and ABO incompatibility.</abstract><cop>Netherlands</cop><pub>Elsevier Inc</pub><pmid>18346838</pmid><doi>10.1016/j.exphem.2008.01.017</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0003-4524-8782</orcidid><orcidid>https://orcid.org/0000-0001-8536-7781</orcidid><orcidid>https://orcid.org/0000-0002-7264-808X</orcidid><orcidid>https://orcid.org/0000-0002-7338-1081</orcidid><orcidid>https://orcid.org/0000-0002-6006-8088</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0301-472X |
| ispartof | Experimental hematology, 2008-05, Vol.36 (5), p.535-544 |
| issn | 0301-472X 1873-2399 |
| language | eng |
| recordid | cdi_hal_primary_oai_HAL_inserm_00484237v1 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Adolescent Adult Advanced Basic Science Aged Antilymphocyte Serum Antilymphocyte Serum - administration & dosage Busulfan Busulfan - administration & dosage Child Child, Preschool Disease-Free Survival Female Follow-Up Studies France Graft vs Host Disease Graft vs Host Disease - diagnosis Graft vs Host Disease - etiology Graft vs Host Disease - therapy Hematologic Neoplasms Hematologic Neoplasms - diagnosis Hematologic Neoplasms - therapy Hematology, Oncology and Palliative Medicine Hematopoietic Stem Cell Transplantation Hematopoietic Stem Cell Transplantation - adverse effects Humans Immunology Infant Life Sciences Male Middle Aged Multivariate Analysis Predictive Value of Tests Registries Remission Induction Retrospective Studies Risk Factors Survival Analysis Time Transplantation Conditioning Transplantation Conditioning - methods Transplantation, Homologous Treatment Outcome Vidarabine Vidarabine - administration & dosage Vidarabine - analogs & derivatives |
| title | Predictive factors for outcomes after reduced intensity conditioning hematopoietic stem cell transplantation for hematological malignancies: a 10-year retrospective analysis from the Société Française de Greffe de Moelle et de Thérapie Cellulaire |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T19%3A24%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Predictive%20factors%20for%20outcomes%20after%20reduced%20intensity%20conditioning%20hematopoietic%20stem%20cell%20transplantation%20for%20hematological%20malignancies:%20a%2010-year%20retrospective%20analysis%20from%20the%20Soci%C3%A9t%C3%A9%20Fran%C3%A7aise%20de%20Greffe%20de%20Moelle%20et%20de%20Th%C3%A9rapie%20Cellulaire&rft.jtitle=Experimental%20hematology&rft.au=Michallet,%20Mauricette&rft.date=2008-05-01&rft.volume=36&rft.issue=5&rft.spage=535&rft.epage=544&rft.pages=535-544&rft.issn=0301-472X&rft.eissn=1873-2399&rft_id=info:doi/10.1016/j.exphem.2008.01.017&rft_dat=%3Cproquest_hal_p%3E69147893%3C/proquest_hal_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=69147893&rft_id=info:pmid/18346838&rft_els_id=1_s2_0_S0301472X08000532&rfr_iscdi=true |